"versionIdentifier","id","uuid:ID","instanceType","rationale"
"2","StudyVersion_1","15a9e297-3643-415a-b280-1f76a57e5507","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
